Certior Financial Group LLC Invests $330,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Certior Financial Group LLC acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 3,572 shares of the biopharmaceutical company's stock, valued at approximately $330,000.

Several other large investors have also added to or reduced their stakes in the business. Norges Bank acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $1,789,254,000. FMR LLC boosted its holdings in shares of Gilead Sciences by 21.6% during the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock worth $3,724,306,000 after buying an additional 7,157,113 shares during the period. Pacer Advisors Inc. grew its stake in Gilead Sciences by 723.3% in the 4th quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company's stock valued at $594,370,000 after buying an additional 5,653,075 shares during the last quarter. Raymond James Financial Inc. bought a new position in Gilead Sciences in the 4th quarter valued at about $207,340,000. Finally, Skandinaviska Enskilda Banken AB publ boosted its holdings in shares of Gilead Sciences by 148.4% during the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 1,817,880 shares of the biopharmaceutical company's stock worth $167,209,000 after acquiring an additional 1,085,987 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on GILD. Royal Bank of Canada lifted their target price on Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a report on Wednesday, February 12th. The Goldman Sachs Group lifted their price objective on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a report on Wednesday, February 12th. Oppenheimer lifted their price objective on shares of Gilead Sciences from $115.00 to $132.00 and gave the company an "outperform" rating in a research note on Tuesday, March 4th. Piper Sandler upped their target price on Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a report on Wednesday, February 12th. Finally, Bank of America boosted their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the company's stock. According to MarketBeat.com, Gilead Sciences has an average rating of "Moderate Buy" and a consensus target price of $105.12.

Remove Ads

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the stock in a transaction on Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the transaction, the chief financial officer now owns 129,873 shares of the company's stock, valued at approximately $12,626,253.06. This trade represents a 52.26 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders sold 302,785 shares of company stock valued at $30,503,250. Insiders own 0.16% of the company's stock.

Gilead Sciences Stock Performance

Gilead Sciences stock traded down $2.95 during mid-day trading on Thursday, reaching $102.30. 7,458,154 shares of the company's stock were exchanged, compared to its average volume of 7,461,033. The firm has a market capitalization of $127.38 billion, a PE ratio of 274.61, a P/E/G ratio of 0.71 and a beta of 0.32. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The business's fifty day simple moving average is $108.17 and its 200 day simple moving average is $96.52. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were issued a $0.79 dividend. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.09%. Gilead Sciences's dividend payout ratio is presently 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.